| Salvatore P Sparich, DO | |
|
50 Roosevelt Ter, Wilkes Barre, PA 18702-3517 | |
| (570) 808-8780 | |
| (570) 808-8785 |
| Full Name | Salvatore P Sparich |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 50 Roosevelt Ter, Wilkes Barre, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326014960 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS009123L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger Wyoming Valley Medical Center | Wilkes barre, PA | Hospital |
| Geisinger Medical Center | Danville, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A potential new male birth control pill has been declared safe for use after a phase I trial showed that the once-daily capsule works without causing any significant side effects.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.
Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza.
A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.
› Verified 5 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A potential new male birth control pill has been declared safe for use after a phase I trial showed that the once-daily capsule works without causing any significant side effects.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.
Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza.
A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.
› Verified 5 days ago
| Entity Name | Caring Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679038293 PECOS PAC ID: 5698004588 Enrollment ID: O20190830001893 |
News Archive
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A potential new male birth control pill has been declared safe for use after a phase I trial showed that the once-daily capsule works without causing any significant side effects.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.
Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza.
A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Salvatore P Sparich, DO 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Salvatore P Sparich, DO 50 Roosevelt Ter, Wilkes Barre, PA 18702-3517 Ph: (570) 808-8780 |
News Archive
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A potential new male birth control pill has been declared safe for use after a phase I trial showed that the once-daily capsule works without causing any significant side effects.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.
Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza.
A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.
› Verified 5 days ago
Dr. Bismah Najeeb, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-808-7399 | |
Weber Wu, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 175 S Wilkes Barre Blvd, Wilkes Barre, PA 18702 Phone: 570-829-2621 Fax: 570-823-4332 | |
Dr. Melita Konecke, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 575 N River St, Wilkes Barre, PA 18764 Phone: 570-552-7260 Fax: 570-552-7268 | |
Dr. Arundev D Desai, MBBS Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1111 E End Blvd, Wilkes Barre, PA 18711 Phone: 570-824-3521 | |
Stephanie A Gill, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 169 N Pennsylvania Ave, Wilkes Barre, PA 18701 Phone: 570-491-0126 Fax: 570-230-0013 | |
Madhavi Madhurapantula, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 25 Church St, Wilkes Barre, PA 18765 Phone: 570-808-3181 Fax: 570-808-8935 | |
Dr. Natasha May Wu, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-808-5484 |